ESCRS - PP21.05 - Why Do We Prefer Fresh Myopic Lenticular In Intrastromal Keratoplasty?

Why Do We Prefer Fresh Myopic Lenticular In Intrastromal Keratoplasty?

Published 2024 - 42nd Congress of the ESCRS

Reference: PP21.05 | Type: Free paper | DOI: 10.82333/36b7-tr04

Authors: Faruk Semiz 1 , Njomza Hima Musa 1 , Zekeriya Alp Demirsoy 1 , Ceren Ece Semiz 1 , Fetih Furkan Arslan* 2

1Ophthalmology,Eye Hospital,Pristina,Kosovo, 2Ophthalmology,Istanbul Universitesi-Cerrahpasa,Istanbul,Türkiye

Purpose

We aim to show that the corneal shape (Q value) changes from conical form to ellipsoid by implanting the thick part of the myopic lenticular into the thinnest part of the advanced keratoconus, according to the topography.

Setting

Eye Hospital,Pristina,Kosovo

Methods

Seventy eyes with advanced keratoconus with corneal transplantation indication were included in this study. Although the fundus examination of advanced keratoconus is normal, the measurements on the autorefractometer are highly myopic (Pseudo myopia). Since the corneas of these patients are very thin and their corneal elasticity is very increased, According to the topography, the central thick part of the myop lenticul is placed intrastromally in the thinnest part of the recipient cornea using the Smile module. The stromal pocket diameter was 8 mm, 2 mm super incision, and 130-μm cap thickness. All patients were followed for three years.

Results

The preoperatively CDVA improvement from 0.87 ± 0.21 logMAR to 0.43 ± 0.09 logMAR  (P < .001) postop 3-year.The preoperatively  CCT increased from 420  ± 6,20 to 530  ± 5,31 μm (P < .001). The preoperatively Q value increased from -0,82 to -0,46 (P < .001).

Conclusions

According to the topography, the corneal Q value changes from conical to ellipsoid after the thick part of the myopic lenticular was placed intrastromal the thin part of the Advanced keratoconus. It is a safe, economical, and reliable technique that increases visual acuity, corneal thickness, and regeneration of healthy keratocyte and telocyte-like cells, extracellular matrix which are vital for stromal regeneration. 
 
ClinicalTrials.gov identifier: NCT04591587.